Preclinical Application of a Fully Human TCR-mimic Antibody Developed to Target NY-ESO-1/HLA-A02
SUMMARY
Biocytogen’s TCRm antibody discovery platform combines unique immune technology with a multiplex screening method to obtain a high-affinity NY-ESO-1/HLA-A02 antibody, which can bind and specifically kill HLA-A02-positive cell lines presenting NY-ESO-1. This TCRm platform overcomes the limitation of targeting extracellular antigens and displays a wider range of applications.
Used in the study: TCR-Mimic Antibody Platform
